Simone Huygens
Overview
Explore the profile of Simone Huygens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smets I, Versteegh M, Huygens S, Wokke B, Smolders J
Mult Scler
. 2024 Jun;
30(8):1016-1025.
PMID: 38859625
Background: Uncertainty about disproportionate impact on health care budgets limits implementation of early highly effective treatment (EHT) in multiple sclerosis (MS). Objective: To estimate cost-effectiveness of escalation versus EHT disease-modifying...
2.
Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, et al.
Per Med
. 2023 Sep;
20(4):321-338.
PMID: 37746727
To explore variations in the cost-effectiveness of entrectinib across different testing strategies and settings. Four testing strategies where adult cancer patients received entrectinib if they tested positive for gene fusions ...
3.
Nagy B, Zelei T, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, et al.
Per Med
. 2023 Sep;
20(4):401-411.
PMID: 37694556
The HEcoPerMed consortium developed a methodological guidance for the harmonization and improvement of economic evaluations in personalized medicine. In three therapeutic areas, health economic models were developed to scrutinize the...
4.
Kovacs G, Nagy D, Szilberhorn L, Zelei T, Gaal Z, Vellekoop H, et al.
Per Med
. 2023 Sep;
20(4):375-385.
PMID: 37694384
Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which...
5.
Szilberhorn L, Zelei T, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, et al.
Per Med
. 2023 Sep;
20(4):387-399.
PMID: 37665262
Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment. A diabetes model was adapted...
6.
Koleva-Kolarova R, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, Szilberhorn L, et al.
Per Med
. 2023 Sep;
20(4):339-355.
PMID: 37665240
The aim of this study was to evaluate the cost-effectiveness of ToxNav, a multivariant genetic test, to screen for followed by personalized chemotherapy dosing for metastatic breast cancer in the...
7.
Koleva-Kolarova R, Szilberhorn L, Zelei T, Vellekoop H, Nagy B, Huygens S, et al.
Per Med
. 2023 Aug;
20(4):305-319.
PMID: 37623911
The implementation of adequate financing and reimbursement of personalized medicine (PM) in Europe is still turbulent. The views and experience of stakeholders about barriers in financing and reimbursing PM and...
8.
Koleva-Kolarova R, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, Szilberhorn L, et al.
Per Med
. 2023 Aug;
20(4):357-374.
PMID: 37577962
The cost-effectiveness and budget impact of introducing extended testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungary were examined. testing with ToxNav...
9.
Smets I, Versteegh M, Huygens S, Corsten C, Wokke B, Smolders J
Mult Scler J Exp Transl Clin
. 2023 Aug;
9(3):20552173231189398.
PMID: 37529628
Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices...
10.
Huygens S, Vellekoop H, Versteegh M, Santi I, Szilberhorn L, Zelei T, et al.
Value Health
. 2022 Oct;
26(2):193-203.
PMID: 36229359
Objectives: This study tackles several challenges of evaluating histology-independent treatments using entrectinib as an example. Histology-independent treatments are provided based on genetic marker(s) of tumors, regardless of the tumor type....